Immobilization of aminothiols on poly(oxyalkylene phosphates). Formation of poly(oxyethylene phosphates)/cysteamine complexes and their radioprotective efficiency. 2002

Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
Department of Radiobiology, National Center of Radiobiology and Radiation Protection, 132 Kl. Ohridski Boulevard, Sofia 1756, Bulgaria.

The necessity to apply near-toxic amounts of radioprotective drugs to achieve adequate protection during radiation treatments represents a major problem in human medicine. One of the promising strategies to suppress the toxicity of these drugs involves their incorporation into biocompatible polymers. In this study cysteamine (Cy) was attached to poly(oxyethylene phosphate), POEP, via an ionic bond. Radioprotection of E. coli B cells by this substance and its acute toxicity on male C57 BL mice were measured. The toxicity of Cy immobilized within the poly(oxyethylene phosphate) was significantly lower in comparison to pure Cy while its radioprotective efficiency remained high at half the maximum tolerable dose. The high radioprotective efficiency of the Cy/POEP complexes was further confirmed on mice at different polymer molecular weight characteristics, drug immobilization degrees, application times, and doses. It was found that POEP with molecular weight 4700 Da and containing 24% repeating units with attached Cy has the highest protection potential combined with a depot effect.

UI MeSH Term Description Entries
D010755 Organophosphates Carbon-containing phosphoric acid derivatives. Included under this heading are compounds that have CARBON atoms bound to one or more OXYGEN atoms of the P( Organophosphate,Phosphates, Organic,Phosphoric Acid Esters,Organopyrophosphates,Acid Esters, Phosphoric,Esters, Phosphoric Acid,Organic Phosphates
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005026 Ethylene Glycols An ethylene compound with two hydroxy groups (-OH) located on adjacent carbons. They are viscous and colorless liquids. Some are used as anesthetics or hypnotics. However, the class is best known for their use as a coolant or antifreeze. Dihydroxyethanes,Ethanediols,Glycols, Ethylene
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014916 Whole-Body Irradiation Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms. Radiation, Whole-Body,Total Body Irradiation,Irradiation, Total Body,Irradiation, Whole-Body,Whole-Body Radiation,Irradiation, Whole Body,Irradiations, Total Body,Irradiations, Whole-Body,Radiation, Whole Body,Radiations, Whole-Body,Total Body Irradiations,Whole Body Irradiation,Whole Body Radiation,Whole-Body Irradiations,Whole-Body Radiations
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
September 1963, International journal of radiation biology and related studies in physics, chemistry, and medicine,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
April 1964, Acta radiologica: therapy, physics, biology,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
September 1965, Doklady Akademii nauk SSSR,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
October 1992, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
July 2005, The journal of physical chemistry. B,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
October 1957, Annales de l'Institut Pasteur,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
March 1971, Radiation research,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
March 2004, Langmuir : the ACS journal of surfaces and colloids,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
November 1996, Pharmaceutical research,
Radostina Georgieva, and Raina Tsevi, and Krassimir Kossev, and Rossitsa Kusheva, and Mariana Balgjiska, and Radostina Petrova, and Violeta Tenchova, and Ivan Gitsov, and Kolio Troev
January 1977, Radiobiologiia,
Copied contents to your clipboard!